Floatz logo

L-Nmma

Hypertensive Disorder

Vanderbilt University Medical CenterPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Hypertensive Disorder cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
OLMESARTAN MEDOXOMIL
Virginia Polytechnic Institute and State University
Phase 4BBB

View all 50 →

Same molecule, other indications

L-Nmma is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
67 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →